REFERENCES
- Bilello K. S., Murin S., Matthay R. A. Epidemiology, etiology, and prevention of lung cancer. Clin. Chest Med. 2002; 23: 1–25
- Blatter M. C., James R. W., Messmer S., et al. Identification of a distinct human high-density lipoprotein-associated protein K-45 identity of K-45 with paraoxonase. Euro. J. Biochem. 1993; 211: 871–879
- Boemi M., Sirolla C., Testa R., Cenerelli S., Fumelli P., James R. W. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabetic Med. 2004; 21(5)423–427
- Brushia R. J., Forte T. M., Oda M. N., La Du B. N., Bielicki J. K. Baculovirus-mediated expression and purication of human serum paraoxonase 1A. J. Lipid Res. 2001; 42: 951–958
- Buege J. A., Aust S. D. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52: 301–310
- Chen H. W., Chien M. L., Chaung Y. H., Lii C. K., Wang T. S. Extracts from cigarette smpke induce DNA damage and cell adhesion molecule expression through different pathways. Chem. Biol. Interact. 2004; 150: 233–241
- Charalabopoulos K., Saaimakopoulos D., Karkabounas V., Karkabounas S., Danielides V., Kiortsis D., Evangelou A. Effects of cigarette smoking on the antioxidant defence in young healthy male volunteers. Int. J. Clin. Pract. 2005; 59: 25–30
- Eckerson H. W., Romson J., Wyte C., La Du B. N. The human serum paraoxonase pol]ymorphism: Identification of phenotypes by their response to salts. Am. J. Hum. Genet. 1993; 35: 214–227
- Feeman W. E. The role of cigarette smoking in atherosclerotic disease: An epidemiologic analysis. J. Cardiovasc. Risk 1999; 6: 333–336
- Isık B., Isık S. R., Ceylan A., Çalık O. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Saudı Med. J. 2005; 26(12)1882–1885
- James R. W., Leviev I., Righetti A. Smoking is associated with reduced paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2252–2257
- Kırkham P., Rahman I. Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther. 2006; 111: 476–494
- MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S–317S
- MacNee W., Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 58S–65S
- Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity and modification of enzymes free thiol. Biochem. Biophys. Res. Commun. 1997; 236: 289–293
- Paredi P., Kharitonov A. S., Leak D., Ward S., Cramer D., Peter J. B. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 369–373
- Pryor W., Stone K. Oxidants in cigarette smoke: Radicals, hydrogen peroxidates, peroxynitreate, peroxynitrite. Ann. NY Acad. Sci. 1993; 686: 12–28
- Rahman I., Schadewijk A. M., Crowther J. L., Hiemstra S., Stolk J., MacNee W., Boer W. I. 4-Hydroxy-2-nonenal a specific lipid peroxidation product is elevated in lungs of patients with chronic obsturictive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 490–495
- Repine J. E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 156: 341–357
- Rodrigo L., Hernandez A. F., Lopez-Caballero J. J., Fernando G., Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue implications for its physiological role. Chem. Biol. Interact. 2001; 137(2)123–137
- Siafakas N. M., Tzortzaki E. G. Few smokers develop COPD. Why?. Respir. Med. 2002; 96: 615–624
- Stanescu D. Identifying smokers at risk of COPD and GOLD. Am. J. Respir. Crit. Care Med. 2003; 168: 500